Mesenchymal Stem Cells and Extracellular Vesicles Derived from Canine Adipose Tissue Ameliorates Inflammation, Skin Barrier Function and Pruritus by Reducing JAK/STAT Signaling in Atopic Dermatitis
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES23(9) · 2022
- 피인용
- Web of Science 30Scopus 32
- FWCI (Scopus)
- 2.04
- JCR IF
- JCR 2021 6.208
- ISSN
- 1661-6596
저자
- Kim, Sung Youl제1저자GNG CELL Co Ltd, R&D Ctr, 122 Unjung Ro, Seongnam Si 13466, South Korea
- Yoon, Tae HongGNG CELL Co Ltd, R&D Ctr, 122 Unjung Ro, Seongnam Si 13466, South Korea
- Na, JungtaeSogang Univ, Dept Life Sci, 35 Baekbeom Ro, Seoul 04107, South Korea
- Yi, Seong JoonKyungpook Natl Univ, Coll Vet Med, Dept Vet Anat, 80 Daehak Ro, Daegu 41566, South Korea
- Jin, YunseokKyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
- Kim, MinjiKyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
- Oh, Tae-Ho교신저자Kyungpook Natl Univ, Coll Vet Med, Dept Vet Internal Med, 80 Daehak Ro, Daegu 41566, South Korea
- 정태욱교신저자Pusan Natl Univ, R&D Ctr, Natl Clin Res Ctr Korean Med, JIN BioCell Co Ltd,Korean Med Hosp, 20 Geumo Ro, Yangsan Si 50612, South Korea
초록
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.Canine atopic dermatitis (AD) is a common chronic inflammatory skin disorder resulting from imbalance between T lymphocytes. Current canine AD treatments use immunomodulatory drugs, but some of the dogs have limitations that do not respond to standard treatment, or relapse after a period of time. Thus, the purpose of this study was to evaluate the immunomodulatory effect of mesenchymal stem cells derived from canine adipose tissue (cASCs) and cASCs-derived extracellular vesicles (cASC-EVs) on AD. First, we isolated and characterized cASCs and cASCs-EVs to use for the improvement of canine atopic dermatitis. Here, we investigated the effect of cASCs or cASC-EVs on DNCB-induced AD in mice, before using for canine AD. Interestingly, we found that cASCs and cASC-EVs improved AD-like dermatitis, and markedly decreased levels of serum IgE, (49.6%, p = 0.002 and 32.1%, p = 0.016 respectively) epidermal inflammatory cytokines and chemokines, such as IL-4 (32%, p = 0.197 and 44%, p = 0.094 respectively), IL-13 (47.4%, p = 0.163, and 50.0%, p = 0.039 respectively), IL-31 (64.3%, p = 0.030 and 76.2%, p = 0.016 respectively), RANTES (66.7%, p = 0.002 and 55.6%, p = 0.007) and TARC (64%, p = 0.016 and 86%, p = 0.010 respectively). In addition, cASCs or cASC-EVs promoted skin barrier repair by restoring transepidermal water loss, enhancing stratum corneum hydration and upregulating the expression levels of epidermal differentiation proteins. Moreover, cASCs or cASC-EVs reduced IL-31/TRPA1-mediated pruritus and activation of JAK/STAT signaling pathway. Taken together, these results suggest the potential of cASCs or cASC-EVs for the treatment of chronic inflammation and damaged skin barrier in AD or canine AD.
키워드
atopic dermatitiscanineextracellular vesicleinflammationmesenchymal stem cellpruritusskin barrier functionALLERGIC AIRWAY INFLAMMATIONCONTACT HYPERSENSITIVITYBONE-MARROWEFFICACYDISEASEBLOODDOGSACTIVATIONEXPRESSIONTGF-BETA-1
식별자
- Scopus EID
- 2-s2.0-85129039168
- WoS UID
- 000794761600001



로그인
연구물 목록으로